Celgene has recently suffered from a series of major setbacks affecting its finances, including the FDA’s refusal to accept its application for a leading late-stage drug.
The management shuffle will leave Celgene CEO and Chairman Mark Alles in charge of the company’s clinical development stages, regulatory focuses and oncology franchise.
Mr. Smith’s exit follows Celgene Executive Chairman Bob Hugin’s departure in February.
“The company is reorganizing its executive team in the meantime, and we could hear several hires [or] promotions over the coming months,” Michael Yee, managing director of Jefferies, an investment banking firm, told Endpoints News.
More articles on supply chain:
Study: 40% of providers have canceled surgeries over supply shortages
10 immensely overinflated hospital costs
Beating Amazon to the punch: Zipline launches drone to deliver medical supplies at 79 mph
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
